MXPA02009376A - Compuestos para direccion al objetivo. - Google Patents

Compuestos para direccion al objetivo.

Info

Publication number
MXPA02009376A
MXPA02009376A MXPA02009376A MXPA02009376A MXPA02009376A MX PA02009376 A MXPA02009376 A MX PA02009376A MX PA02009376 A MXPA02009376 A MX PA02009376A MX PA02009376 A MXPA02009376 A MX PA02009376A MX PA02009376 A MXPA02009376 A MX PA02009376A
Authority
MX
Mexico
Prior art keywords
compounds
compound
caspase
cytotoxic
constitutively active
Prior art date
Application number
MXPA02009376A
Other languages
English (en)
Inventor
Agamemnon Antoniou Epenetos
Original Assignee
Antisoma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Res Ltd filed Critical Antisoma Res Ltd
Publication of MXPA02009376A publication Critical patent/MXPA02009376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22056—Caspase-3 (3.4.22.56)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22059—Caspase-6 (3.4.22.59)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto que comprende una porcion especifica de celulas objetivo y una porcion citotoxica, caracterizado porque la porcion citotoxica del compuesto es una caspasa constitutivamente activa o tiene sustancialmente la misma actividad inductora de apoptosis que las caspasas. Alternativamente, la invencion proporciona un compuesto que comprende una porcion mediadora Y una porcion citotoxica, caracterizado porque la porcion citotoxica del compuesto es una caspasa. Constitutivamente activa o tiene sustancialmente la misma actividad inductora de apoptosis que las caspasas. Preferentemente, la porcion citotoxica de los compuestos de la invencion es una caspasa 3, caspasa 6 o caspasa 7, constitutivamente activas. La invencion proporciona ademas acidos nucleicos que codifican para los compuestos de la invencion, y el uso de tales compuestos en medicina, por ejemplo en el tratamiento de cancer.
MXPA02009376A 2000-03-28 2001-03-28 Compuestos para direccion al objetivo. MXPA02009376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007343A GB2360771A (en) 2000-03-28 2000-03-28 Compounds for targeting
PCT/GB2001/001354 WO2001072336A1 (en) 2000-03-28 2001-03-28 Compounds for targeting

Publications (1)

Publication Number Publication Date
MXPA02009376A true MXPA02009376A (es) 2004-05-14

Family

ID=9888460

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009376A MXPA02009376A (es) 2000-03-28 2001-03-28 Compuestos para direccion al objetivo.

Country Status (21)

Country Link
EP (1) EP1267940B1 (es)
JP (1) JP2003528156A (es)
KR (1) KR20030022782A (es)
CN (1) CN1420789A (es)
AT (1) ATE240122T1 (es)
AU (1) AU4850101A (es)
BR (1) BR0109570A (es)
CA (1) CA2402453A1 (es)
DE (1) DE60100274T2 (es)
DK (1) DK1267940T3 (es)
ES (1) ES2202287T3 (es)
GB (2) GB2360771A (es)
IL (1) IL151675A0 (es)
MX (1) MXPA02009376A (es)
NO (1) NO20024587L (es)
NZ (1) NZ521289A (es)
PL (1) PL358482A1 (es)
PT (1) PT1267940E (es)
RU (1) RU2002128746A (es)
WO (1) WO2001072336A1 (es)
ZA (1) ZA200207157B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406137A (zh) * 2000-02-24 2003-03-26 杰南技术公司 天冬氨酸特异性半胱氨酸蛋白酶活化的前体药物治疗
US7125839B2 (en) 2002-02-07 2006-10-24 Massachusetts Institute Of Technology Anti-pathogen treatments
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN114173809A (zh) * 2019-04-02 2022-03-11 伊缪纯有限公司 免疫刺激组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
AU660297B2 (en) * 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
AU5615594A (en) * 1992-11-13 1994-06-08 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
GB2300859B (en) * 1993-01-15 1997-06-18 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a further portion
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6379950B1 (en) * 1998-01-09 2002-04-30 Thomas Jefferson University Recombinant, active caspases and uses thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities

Also Published As

Publication number Publication date
AU4850101A (en) 2001-10-08
EP1267940B1 (en) 2003-05-14
DK1267940T3 (da) 2003-09-08
DE60100274D1 (de) 2003-06-18
CN1420789A (zh) 2003-05-28
ATE240122T1 (de) 2003-05-15
NO20024587D0 (no) 2002-09-25
KR20030022782A (ko) 2003-03-17
GB2360772B (en) 2002-05-22
GB0107725D0 (en) 2001-05-16
GB2360771A (en) 2001-10-03
NZ521289A (en) 2004-04-30
PL358482A1 (en) 2004-08-09
GB2360772A (en) 2001-10-03
RU2002128746A (ru) 2004-03-27
PT1267940E (pt) 2003-09-30
DE60100274T2 (de) 2004-04-01
BR0109570A (pt) 2003-01-28
NO20024587L (no) 2002-11-25
CA2402453A1 (en) 2001-10-04
ZA200207157B (en) 2003-12-05
EP1267940A1 (en) 2003-01-02
GB0007343D0 (en) 2000-05-17
ES2202287T3 (es) 2004-04-01
JP2003528156A (ja) 2003-09-24
IL151675A0 (en) 2003-04-10
WO2001072336A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
MY129809A (en) Quinazoline derivatives
DE69905368D1 (en) Oxydiertes thymosin beta 4
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
GB9907571D0 (en) Compounds
MXPA02009376A (es) Compuestos para direccion al objetivo.
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
SI1003554T1 (en) Proton pump inhibitor in therapeutic combination with antibacterial substances
WO2003059395A3 (fr) Antisens diriges contre le csf-1 humain
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE59805112D1 (de) Chimäre oligonucleotide und ihre verwendung
WO2004024877A3 (en) Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent
WO2001018202A3 (en) Flint analog compounds and formulations thereof
ZA992063B (en) Suicide gene therapy system for the treatment of brain tumours.
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
ZA200007494B (en) Use of inhibitors of protein kinase C epsilon to treat pain.